Ozempic

Stories 1 - 20 |  Next >>

Medicare Announces Lower Prices for 15 Drugs

Negotiations were made possible by Biden-era law

(Newser) - The Trump administration has revealed new, lower prices for 15 widely used prescription drugs, the result of Medicare negotiations with pharmaceutical companies that are expected to save the government billions of dollars. The list covers medications for conditions such as cancer, diabetes, lung conditions, and depression, the New York Times...

Semaglutide Fails to Slow Alzheimer's in Major Trials

Major trials show no benefit for early Alzheimer's patients

(Newser) - A closely anticipated trial has concluded with disappointing results for Novo Nordisk's blockbuster drug semaglutide, the active ingredient in Ozempic and Wegovy. The company announced on Monday that two large studies found the drug did not slow cognitive decline or improve daily functioning in people with early Alzheimer's...

Survey Reveals Widespread Usage of GLP-1 Drugs

Almost 1 in 5 US adults have tried one, and 1 in 8 are using them now: KFF

(Newser) - About one in eight American adults are now taking GLP-1 drugs like Ozempic, Wegovy, Zepbound, and Mounjaro, a new survey shows—a sharp increase from just 18 months ago. These medications, approved in the US only four years ago for obesity, are quickly becoming some of the most widely prescribed,...

Patients With Colon Cancer May See Extra GLP-1 Benefits

Those on weight loss drugs like Ozempic, Wegovy see lower death rates than those not taking them

(Newser) - Medications like Wegovy and Ozempic, known for managing diabetes and promoting weight loss, may also be linked to significantly lower death rates in colon cancer patients, according to a new study cited by the Independent . Researchers at UC San Diego reviewed medical records for more than 6,800 colon cancer...

Attendee's Collapse Interrupts Oval Office News Conference

White House's Mehmet Oz helped the man, who is said to be OK

(Newser) - A White House press conference took an unexpected turn Thursday when one of the attendees collapsed, reports People . White House officials hustled reporters out of the room, and President Trump said later that the man was OK. "You saw he went down. And he's fine," Trump said,...

Costco Is Hawking Ozempic, Wegovy at Pharmacies

Members would pay $499 a month without insurance

(Newser) - Costco is getting in on the surging popularity of weight-loss drugs. The warehouse chain is bringing the blockbuster drugs Ozempic and Wegovy to its pharmacies in the US, reports the New York Times . Members with a prescription can purchase a four-week supply of either drug for $499—roughly half...

Health Insurance Is Set for a Steep Hike

Expiring ACA subsidies, pricey new drugs could drive premiums higher

(Newser) - Americans can expect a significant jump in health insurance premiums over the next couple of years, with costs set for the largest increase in at least half a decade. Multiple industry surveys project that businesses will see premiums rise by 9% or more in 2026—costs likely to trickle...

Maker of Ozempic, Wegovy Slashes 9K Jobs

Cost-saving overhaul by Novo Nordisk follows profit warning, fierce competition in obesity drug market

(Newser) - Novo Nordisk, the Danish pharmaceutical giant known for manufacturing Ozempic and Wegovy, has announced plans to slash about 9,000 jobs—roughly 11% of its global workforce—in an effort to streamline operations and rein in costs. The company says the cuts will take place immediately, and that staffers...

GLP-1 Drugs Now Considered Essential Medicines

Semaglutide, tirzepatide join WHO list in hope of boosting access in low-income countries

(Newser) - For the first time, the World Health Organization has named popular GLP-1 weight loss drugs as essential medicines, a move set to reshape access to the treatments in countries with limited healthcare resources. The move means semaglutide, the active ingredient in Novo Nordisk's Ozempic, and tirzepatide, the active...

Ozempic Maker Takes Sales Hit as Rivals, Tariffs Loom

Eli Lilly rivalry hits Europe's top drugmaker hard

(Newser) - Novo Nordisk, the Danish pharma heavyweight behind Ozempic, is feeling the squeeze as its once-booming diabetes drug sales slow. The company's GLP-1 injectables, key players in the diabetes and weight loss boom, saw their sales growth plummet to 8% in the first half of this year—down from...

Weight Loss Drugs May Soon Fall Under Medicare/Medicaid

Trump administration pilot program could bring pricey GLP-1 drugs to millions of Americans

(Newser) - The Trump administration is preparing a five-year test that could allow some Medicare and Medicaid patients to access high-profile weight loss drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound. The plan, which would let state Medicaid programs and Medicare Part D insurers choose to cover these drugs for obesity treatment,...

The GLP-1 Drug Landscape Changes on Thursday

Off-brand Ozempic products will no longer be permitted to be sold

(Newser) - The GLP-1 drug landscape is about to change. Starting Thursday, off-brand versions of semaglutide will no longer be permitted to be sold—creating a possible problem for the Americans who've come to rely on the generally cheaper option. The FDA in February announced that the shortage of the active...

Mounjaro Beats Ozempic in Head-to-Head Study
Mounjaro Beats Ozempic
in Head-to-Head Study
new study
May 12, 2025 5:04 PM CDT

Mounjaro Beats Ozempic in Head-to-Head Study

Study suggests tirzepatide users lose more weight than semaglutide users

(Newser) - Mounjaro wins bragging rights over Ozempic in a new weight-loss study—though it's one that was funded by the maker of Mounjaro. Researchers found that those taking tirzepatide, marketed as Mounjaro and Zepbound, lost about 20% of their body weight over 72 weeks, according to the study published...

Former FDA Chief Praises 'Revolutionary' GLP-1s

'These drugs offer a chance for people to improve their health even as our national body is ill'

(Newser) - "Revolutionary" anti-obesity drugs like Ozempic appear to be the right tool to deal with the addictive, highly processed foods that are ruining Americans' health, former FDA Commissioner David Kessler writes at the New York Times . He says GLP-1 drugs helped him end the "cycle of despair" of weight...

New Superpower of Ozempic, Wegovy: Reversing Liver Disease

Semaglutide found to reduce inflammation, scarring in people with severe form of fatty liver disease

(Newser) - Experts exploring what other conditions semaglutide, the active ingredient in Wegovy and Ozempic, might help apart from diabetes and weight loss say the results of a Phase 3 clinical trial suggest it may reverse a common liver disease. Some 15 million US adults have metabolic dysfunction-associated steatohepatitis (MASH), an advanced...

Spending on GLP-1 Drugs Has Skyrocketed

Spending increased 500% from 2018 to 2023, reaching nearly $72B

(Newser) - It's not just talk. Americans' spending on GLP-1 drugs including Ozempic and Wegovy has skyrocketed in the last five years. Spending hit $71.7 billion in 2023 for a 500% increase from $13.7 billion in 2018, according to a research letter published this month in JAMA Network Open...

It's Basically Ozempic, but in Pill Form

Eli Lilly's orforglipron appears as effective at lowering blood sugar, aiding weight loss in diabetes patients

(Newser) - Scared of needles but intrigued by injectable drugs that help manage blood sugar levels? You'll be happy to know Eli Lilly has created a GLP-1 agonist in pill form, and it may be just as effective at lowering blood sugar and aiding weight loss in people with Type 2...

Pfizer Halts Obesity Pill Tests Amid Safety Concerns

Phase 3 trial for danuglipron has been paused due to potential liver injury

(Newser) - Pfizer's pursuit of a daily pill to tackle obesity has hit a setback. The pharmaceuticals giant has paused development of its oral obesity drug, danuglipron, after a possible liver injury experienced by a trial participant. The incident occurred during phase 3 testing, the final stage before seeking regulatory...

FDA Change on Ozempic to Shake Up the Market
FDA Change on Ozempic
to Shake Up the Market
in case you missed it
Mar 1, 2025 11:00 AM CST

FDA Change on Ozempic to Shake Up the Market

Active ingredient no longer officially is in shortage, so imitators may have to drop out

(Newser) - The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher costs for users and lower income for companies selling off-brand versions of the weight-loss drugs. On Friday, the FDA updated its database to show the shortage of the active...

Pharma Group Wants to Block 'Dangerous' Super Bowl Ad

Lobbyists say Hims & Hers promo for weight-loss medication 'misleading,' 'deeply troubling'

(Newser) - Even folks who aren't into football tune into the Super Bowl for its ads, but this year there's some "big drama" around one that's set to air on Sunday, reports Quartz . A pharmaceuticals industry group is slamming a "dangerous" advertisement from Hims & Hers, asking...

Stories 1 - 20 |  Next >>
Most Read on Newser